Search
Karyopharm Therapeutics Inc
KPTIAdd to Watchlist
7.140USD
-0.530-6.91%
Close 05/18, 16:00（ET）Quotes delayed by 15 min
161.81MMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-6.91%
5 Days
-18.96%
1 Month
-17.07%
6 Months
+14.42%
Year to Date
-2.99%
1 Year
+34.21%
TradingKey Stock Score of Karyopharm Therapeutics Inc
Currency: USD Updated: 2026-05-18Key Insights
Karyopharm Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 95 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.40.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Karyopharm Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Karyopharm Therapeutics Inc Highlights
StrengthsRisks
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 146.07M.
Overvalued
The company’s latest PE is -0.44, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 14.10M shares, increasing 26.39% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 105.41K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.28.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
13.400
Target Price
+74.71%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Karyopharm Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Karyopharm Therapeutics Inc Info
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Ticker SymbolKPTI
CompanyKaryopharm Therapeutics Inc
CEOPaulson (Richard A)
Websitehttps://karyopharm.com/
Related Instruments
-1.67%
+0.97%
-0.47%
+0.72%
+1.29%
+1.06%
-0.59%
+0.07%
-1.03%
0.00%
+0.54%
-0.08%
+1.99%
+1.19%
+2.02%
0.00%
-9.82%
-0.24%
-2.88%
+2.34%Popular Instruments
102.433
-0.023 (-0.02%)
297.840
-2.390 (-0.80%)
222.320
-3.000 (-1.33%)
4556.140
-9.980 (-0.22%)
458.680
-23.340 (-4.84%)
1333.010
-74.600 (-5.30%)
681.540
-43.120 (-5.95%)
396.940
+0.160 (+0.04%)
76647.340
-232.580 (-0.30%)
409.990
-12.250 (-2.90%)
